PeptideDDP
Global Peptide Logistics
Market notes, buyer education and peptide logistics industry trends.
Liraglutide reduced proteinuria and kidney injury in lupus-prone mice without changing autoantibody levels, extending GLP-1 research toward lupus nephritis.
Read article →A diaTribe review catalogues seven GLP-1 effects beyond glucose control, but only Zepbound for sleep apnea and Wegovy for MASH carry FDA approval.
Read article →Lilly reports retatrutide cut 20.9% of body weight at 80 weeks versus 9.4% for Ozempic and lowered A1C more, a company-reported result with full data still pending.
Read article →Eli Lilly Canada says Health Canada approved Mounjaro (tirzepatide) for glycemic control in patients aged 10 to 17 with type 2 diabetes, a first for a once-weekly GIP/GLP-1…
Read article →A 2026 records study finds fewer falls on semaglutide or tirzepatide in older adults with diabetes, while Wegovy's label flags more hip and pelvic fractures in patients 75…
Read article →Retatrutide, an unapproved triple-receptor agonist nicknamed GLP-3, is in late-stage trials with attributed 70-pound and 20-25% weight-loss figures, while illegal Reta sales draw FDA letters.
Read article →A 2026 impurity finding in compounded tirzepatide-vitamin B12 samples and a 22-vial recall sharpen the debate over GLP-1 compounding after FDA resolved the shortages.
Read article →A BioPharma APAC census finds 30 Asia-Pacific-discovered obesity assets in human trials, 21 from mainland China, with three 2026 approvals and three Chinese GLP-1/GIP duals filed with the…
Read article →Lilly reports retatrutide roughly doubled Ozempic's weight loss and cut A1c further in TRANSCEND-T2D-2, but the triple-agonist peptide remains unapproved.
Read article →HDM7006, a GLP-1/GIP dual agonist, shows a 40–52 hour half-life and low immunogenicity in healthy cats, supporting once-weekly dosing in a preclinical study.
Read article →